<DOC>
	<DOCNO>NCT02628600</DOCNO>
	<brief_summary>This open-label safety extension study assess safety tolerability daily dose 590 mg Liposomal Amikacin Inhalation ( LAI ) add multi-drug regimen subject non-tuberculous mycobacterium ( NTM ) lung infection due Mycobacterium avium complex ( MAC ) refractory therapy Study INS-212 .</brief_summary>
	<brief_title>Open-label Safety Extension Study Assessing Safety Tolerability LAI Patients Who Participated Study INS-212</brief_title>
	<detailed_description />
	<mesh_term>Amikacin</mesh_term>
	<criteria>Key 1. successfully complete Month 6 End Treatment visit Study INS212 2. achieve INS212 protocol definition culture conversion Month 6 Study INS212 OR experience relapse recurrence Month 6 Study INS212 . Key 1. achieve culture conversion without relapse recurrence Study INS212 study Month 6</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>